The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A randomized phase III study comparing paclitaxel-BEP (T-BEP) to standard BEP in patients with in intermediate prognosis germ cell cancer (GCC): An intergroup study of EORTC, German TCSG/AUO, MRC, and Spanish GCC group (EORTC 30983).
R. De Wit
No relevant relationships to disclose
I. A. Skoneczna
No relevant relationships to disclose
K. Gedske Daugaard
No relevant relationships to disclose
M. de Santis
No relevant relationships to disclose
A. Garin
No relevant relationships to disclose
N. Aass
No relevant relationships to disclose
J. A. Witjes
No relevant relationships to disclose
P. Albers
No relevant relationships to disclose
J. White
No relevant relationships to disclose
J. R. Germa-Lluch
No relevant relationships to disclose
S. Osanto
No relevant relationships to disclose
S. Marreaud
No relevant relationships to disclose
L. Collette
No relevant relationships to disclose